Financials data is unavailable for this security.
Cash flow in USDView more
In 2024, Immunovant Inc increased its cash reserves by 68.74%, or 258.83m. Cash Flow from Financing totalled 472.43m or -- of revenues. In addition the company used 214.23m for operations while cash used for investing totalled 360.00k.
Cash flow per share | -2.22 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 3.06 |
---|---|
Tangible book value per share | 3.06 |
More ▼
Balance sheet in USDView more
Current ratio | 7.61 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼